ProQR Therapeutics N.V. — 2019 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2019; filed March 31, 2020. This is an annual report, not a standalone fourth-quarter filing, and it does not provide separate Q4 financial results. Financial statements are audited and prepared under IFRS, with amounts generally reported in euros.
Business context
ProQR is a clinical-stage biotechnology company developing RNA-based medicines for rare genetic diseases, with a focus on inherited retinal disorders. It had no products on the market and had generated no product or royalty revenue. Its lead clinical programs included sepofarsen for LCA10, QR-421a for Usher syndrome and related retinal disease, and QR-1123 for autosomal dominant retinitis pigmentosa. The company also had earlier-stage programs and its Axiomer RNA-editing platform.
Key financial metrics
| Metric (€ in thousands, except per-share data) | 2019 | 2018 |
|---|---|---|
| Other income, primarily grants | 1,933 | 5,761 |
| Research and development costs | 46,491 | 29,514 |
| General and administrative costs | 12,887 | 12,540 |
| Operating loss | (57,445) | (36,293) |
| Net loss | (56,746) | (37,086) |
| Basic and diluted loss per share | €(1.38) | €(1.08) |
| Cash and cash equivalents at year-end | 111,950 | 105,580 |
| Total assets | 117,535 | 110,231 |
| Total liabilities | 23,702 | 17,546 |
| Total equity | 93,833 | 92,685 |
There were no product sales, so conventional gross margin measures are not meaningful. Cash used in operating activities was €43.970 million, versus €28.493 million in 2018; investing activities used €0.580 million. Financing activities provided €50.199 million, primarily reflecting net proceeds of €48.550 million from an October 2019 share offering. Year-end borrowings were €13.052 million, including government innovation credit and convertible loans; lease liabilities were €0.508 million.
Material changes versus 2018
- R&D spending increased by €16.977 million, principally with progression of sepofarsen, QR-421a and QR-1123 clinical programs, increased external study and staffing costs, and payments under the Ionis license.
- Net loss increased by €19.660 million. Lower grant and other income partly contributed to the higher operating loss.
- Operating cash use increased by €15.477 million. Cash nevertheless rose by €6.370 million, supported mainly by the 2019 equity offering and currency effects.
- Weighted-average shares outstanding increased to 41.0 million from 34.1 million. The filing reports 49,745,687 shares outstanding at year-end; the financial statements show 53,975,838 issued shares, including 4,230,151 treasury shares.
Outlook, risks and unusual items
- Management estimated that year-end cash would fund planned operations into the second half of 2022. This estimate depended on assumptions and could change with development costs, trial timing, financing needs or other events.
- COVID-19 developments disclosed after year-end had delayed ongoing and scheduled trials, including the pivotal sepofarsen trial. Management described mitigation efforts, but could not assure that enrollment and development timelines would recover as planned.
- Sepofarsen’s completed Phase 1/2 study showed reported improvements in vision-related measures, with lens opacities and some retinal findings among reported safety observations. These early results do not establish efficacy in the ongoing pivotal trial.
- March 2020 interim QR-421a results, reported after year-end but before filing, showed no serious adverse events in the small group treated to date; two of eight treated patients were reported to have benefit across multiple measures. These preliminary findings require confirmation in the continuing study.
- Potential future obligations include up to $37.5 million in milestone payments to Foundation Fighting Blindness following QR-421a’s first commercial sale, and Ionis development and sales milestone payments plus royalties stated in the filing as 20% of net sales. These are contingent obligations, not current product-sale costs.
- Research and development commitments were €19.472 million at year-end, including €10.234 million due in 2020. The company also disclosed a €13.377 million lease commitment and significant future lease payments under its new facility agreement.
- The company reported no material litigation proceedings at year-end, no off-balance-sheet arrangements and no dividends. It reported effective disclosure controls and internal control over financial reporting; the auditor gave unqualified opinions on the financial statements and internal controls.
- After year-end, ProQR entered a new at-the-market sales agreement allowing up to $75 million of share offerings, subject to the agreement’s terms. Future use could dilute existing shareholders.
Important facts for investors to verify
- Whether COVID-19-related trial delays affected enrollment, timelines, costs or the stated cash runway, and how much cash remained after year-end.
- Subsequent clinical data, safety findings and regulatory milestones for sepofarsen, QR-421a and QR-1123; the cited results are early-stage or interim.
- Expected cash burn, financing plans and any use of the $75 million ATM facility, including the resulting dilution.
- Timing and potential funding impact of contingent license, milestone, royalty and research commitments, especially FFB and Ionis obligations.
- The share-count presentation: reconcile year-end issued shares, treasury shares and outstanding shares when assessing dilution and ownership.